Tags

Type your tag names separated by a space and hit enter

Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients.
Transplant Cell Ther. 2021 Jul 19 [Online ahead of print]TC

Abstract

Immunocompromised individuals were not included in formal trials of SARS-CoV-2 mRNA vaccines. Subsequent studies in patients with hematologic malignancies and solid organ transplantation recipients suggest inferior responses to vaccination. We determined antibody responses to a single dose of vaccines in one of the most vulnerable patient groups, allogeneic hematopoietic cell transplantation (allo-HCT) recipients. Pfizer-BioNTech (PB) or AstraZeneca (AZ) SARS-CoV-2 vaccines were administered at least 3 months post-transplantation to 55 adult allo-HCT recipients. We found that older age and concurrent use of immunosuppressive medications were significantly associated with lack of antibody response to vaccination. Only 21% of patients on systemic immunosuppression mounted a response, compared with 58% of patients not on immunosuppression (P = .006). We also show that responses to the AZ vaccine may be superior to responses to the PB vaccine in this cohort. These findings highlight the need for novel immunogenic vaccine formulations and schedules in these highest-risk patients, as well as continued public healthy safety measures to protect the most vulnerable members of our society.

Authors+Show Affiliations

The Royal Marsden NHS Hospital, Sutton, United Kingdom. Electronic address: sandra.easdale@rmh.nhs.uk.The Royal Marsden NHS Hospital, Sutton, United Kingdom.The Royal Marsden NHS Hospital, Sutton, United Kingdom.The Royal Marsden NHS Hospital, Sutton, United Kingdom.The Royal Marsden NHS Hospital, Sutton, United Kingdom.The Royal Marsden NHS Hospital, Sutton, United Kingdom.The Royal Marsden NHS Hospital, Sutton, United Kingdom.The Royal Marsden NHS Hospital, Sutton, United Kingdom.The Royal Marsden NHS Hospital, Sutton, United Kingdom.The Royal Marsden NHS Hospital, Sutton, United Kingdom.The Royal Marsden NHS Hospital, Sutton, United Kingdom.The Royal Marsden NHS Hospital, Sutton, United Kingdom.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34293520

Citation

Easdale, Sandra, et al. "Serologic Responses Following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients." Transplantation and Cellular Therapy, 2021.
Easdale S, Shea R, Ellis L, et al. Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients. Transplant Cell Ther. 2021.
Easdale, S., Shea, R., Ellis, L., Bazin, J., Davis, K., Dallas, F., Thistlethwayte, E., Ethell, M., Potter, M., Arias, C., Anthias, C., & Nicholson, E. (2021). Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients. Transplantation and Cellular Therapy. https://doi.org/10.1016/j.jtct.2021.07.011
Easdale S, et al. Serologic Responses Following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients. Transplant Cell Ther. 2021 Jul 19; PubMed PMID: 34293520.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients. AU - Easdale,Sandra, AU - Shea,Robyn, AU - Ellis,Lauren, AU - Bazin,Jessica, AU - Davis,Kim, AU - Dallas,Fiona, AU - Thistlethwayte,Emma, AU - Ethell,Mark, AU - Potter,Mike, AU - Arias,Carlos, AU - Anthias,Chloe, AU - Nicholson,Emma, Y1 - 2021/07/19/ PY - 2021/05/27/received PY - 2021/07/08/revised PY - 2021/07/11/accepted PY - 2021/7/23/pubmed PY - 2021/7/23/medline PY - 2021/7/22/entrez KW - Allogeneic stem cell transplantation KW - COVID vaccination KW - SARS-CoV-2 antibody response JF - Transplantation and cellular therapy JO - Transplant Cell Ther N2 - Immunocompromised individuals were not included in formal trials of SARS-CoV-2 mRNA vaccines. Subsequent studies in patients with hematologic malignancies and solid organ transplantation recipients suggest inferior responses to vaccination. We determined antibody responses to a single dose of vaccines in one of the most vulnerable patient groups, allogeneic hematopoietic cell transplantation (allo-HCT) recipients. Pfizer-BioNTech (PB) or AstraZeneca (AZ) SARS-CoV-2 vaccines were administered at least 3 months post-transplantation to 55 adult allo-HCT recipients. We found that older age and concurrent use of immunosuppressive medications were significantly associated with lack of antibody response to vaccination. Only 21% of patients on systemic immunosuppression mounted a response, compared with 58% of patients not on immunosuppression (P = .006). We also show that responses to the AZ vaccine may be superior to responses to the PB vaccine in this cohort. These findings highlight the need for novel immunogenic vaccine formulations and schedules in these highest-risk patients, as well as continued public healthy safety measures to protect the most vulnerable members of our society. SN - 2666-6367 UR - https://www.unboundmedicine.com/medline/citation/34293520/Serological_responses_following_a_single_dose_of_SARS-CoV-2_vaccination_in_allogeneic_stem_cell_transplant_recipients. L2 - https://linkinghub.elsevier.com/retrieve/pii/S2666-6367(21)01076-9 DB - PRIME DP - Unbound Medicine ER -